

USF Physicians Group

University of South Florida College of Medicine
Division of Neurological Surgery and Rehabilitation

1008 '99 OCT 19 P2:00

ACADEMIC FACULTY NEUROSURGERY

David W. Cahill, M.D., F.A.C.S.
Director
Neurovascular and Spinal Surgery
(813) 259-0904

Joseph Ransohoff, M.D.
Director of Neurosurgery
James A. Haley Veterans'
Administration Hospital
(813) 972-7578

Steven S. Brem, M.D.
Director of Neurosurgery
H. Lee Moffitt Cancer Center
Neuro-oncology
(813) 979-3063

Thomas B. Freeman, M.D.
General Neurosurgery and
Neuroendocrine Surgery
(813) 259-0889

Lucy C. Love, M.D., F.A.C.S.
Pediatric and General Neurosurgery
(813) 259-0892

Donald A. Smith, M.D.
Stereotaxis, Radiosurgery, Skull Base
and General Neurosurgery
(813) 259-0892

Fernando L. Vale, M.D.
Epilepsy and Functional Neurosurgery
(813) 259-0605

NEUROLOGY

Selim R. Benbadis, M.D.
Epilepsy and Sleep Disorders
(813) 259-0605

PHYSICAL MEDICINE & REHABILITATION

Naomi Abel, M.D.
(813) 259-0894

Susan Alden, M.D.
(813) 259-0931

Kanta Shah, M.D.
(813) 259-0931

RESEARCH FACULTY

Paul R. Sanberg, Ph.D., D. Sc.
Director of Research
(813) 974-3154

Alison E. Willing, Ph.D.
R. Douglas Shytle, Ph.D.
Sam Saporta, Ph.D.
Don F. Cameron, Ph.D.
Gary Arendash, Ph.D.
Toru Shimizu, Ph.D.

ADMINISTRATIVE STAFF

Donna Price
Administrative Assistant
(813) 259-0904 • Fax (813) 259-0858

JoAnn With
Divisional Manager
(813) 259-0887

CLINICAL OFFICES

Harbourside Medical Tower
4 Columbia Drive, Suite 730
Tampa, Florida 33606
Fax (813) 259-0900

H. Lee Moffitt Cancer Center
12901 Magnolia Drive
Tampa, Florida 33612

James A. Haley Veteran's
Administration Hospital
13000 Bruce B. Downs Boulevard (VA 112)
Tampa, Florida 33612

RESEARCH OFFICES

University of South Florida
12901 Bruce B. Downs Blvd., MDC 16
Tampa, Florida 33612
(813) 974-3154 • Fax (813) 974-3078

October 13, 1999

Dockets Management Branch (HFA-305)

Food and Drug Administration

5630 Fishers Lane, Room 1061

Rockville, Maryland 20852

**RE: Docket #99D-3082: International Conference of Harmonization;
Choice of Control Group in Clinical Trials**

To Whom it May Concern:

I have recently reviewed your notice regarding the above mentioned document. I have several concerns about this document. As a surgeon that is attempting to modify the way that surgical trials are performed, in favor of increased of safety for patients both in the trial phase as well as clinical phase of therapeutic development, the proposed docket is inadequate from several perspectives. It provides no guidance whatsoever on the assessment of risk versus benefit in a trial design, nor does it give guidance on the reasonableness of a decision regarding this matter. This is, of course, critical in particular in surgical trials where risk-related issues, if anything, are magnified. It gives no guidance as to who will make such decisions.

It does not begin to go far enough to address the issue of who benefits from a clinical trial: the subject in the current trial, a subject in (for example) a cross-over arm, patients with a similar disease, or society in general. As far as I can tell, the most that a patient can be asked to consent to is the experience of discomfort as well as a delay in therapy, and in the latter case only if it is deemed acceptable. Many studies involve more than minimal risk, and these guidelines would make it nearly impossible to design an effective trial of many invasive therapies.

In summary, I find nothing in these guidelines to provide adequate protection of subjects from the current method of relatively uncontrolled development of surgical and invasive therapies. I maintain that the voluntary participation of a small number of subjects in a study with defined and reasonable risks is far more ethical than the involuntary exposure of hundreds or thousands of unknowing patients to an operation of unknown risks and unproven benefits. I am afraid that this current document does not begin to provide adequate protection for patients that are offered unproven surgical and invasive therapies.

99D-3082

C 1

PAGE TWO
DOCKETS MANAGEMENT BRANCH (HFA-305
FOOD AND DRUG ADMINISTRATION
OCTOBER 13, 1999

Sincerely yours,

A handwritten signature in black ink that reads "Thomas B. Freeman". The signature is written in a cursive, flowing style with a long horizontal stroke at the end.

Thomas B. Freeman, M.D., F.A.C.S.
Professor
Department of Neurosurgery

TBF:fm


Dictated, but not read by.

CC: Robert Temple
Center for Drug Evaluation and Research (HFD-4)
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Mark Walton, M.D.
Branch Chief
Medicine Branch
Division of Clinical Trial Design Analysis (HFM 573)
1401 Rockville Pike, Suite 200 North
Rockville, Maryland 20852

Dorothy E. Vawter, Ph.D.
Associate Director
Minnesota Center for Health Care Ethics
The College of St. Catherine-Minneapolis
601 - 25th Avenue South
Minneapolis, Mn 55454

USF Physicians Group
University of South Florida College of Medicine
Department of Neurological Surgery
Harbourside Medical Tower
4 Columbia Drive, Suite 730
Tampa, Florida 33606



Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, Maryland 20852

20852-0001

20852

